Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aeglea BioTherapeutics, Inc. (AGLE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
Docs: "Aeglea BioTherapeutics, Inc. Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 235,358 $ 34,863 Marketable securities — 20,848 Development receivables 1,646 375 Prepaid expenses and other current assets 2,882 6,172 Total current assets 239,886 62,258 Restricted cash 1,317 1,553 Property and equipment, net — 3,220 Operating lease right-of-use assets 2,316 3,430 Other non-current assets 10 683 TOTAL ASSETS $ 243,529 $ 71,144 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable $ 2,854 $ 677 Forward contract liability 164,382 — CVR liability 10,500 — Operating lease liabilities 4,331 625 Deferred revenue 930 517 Accrued and other current liabilities 28,427 12,837 Related party accounts payable 20,810 — ..."
05/11/2023 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results $39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023"
03/02/2023 8-K Investor presentation, Quarterly results
Docs: "Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates Jeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, which is expected to fund operations into the fourth quarter of 2023",
"7.0 14.0 21.5 36.0 ER FR PR NR"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights PEACE baseline data at upcoming medical meeting underscore disease severity and significant limitations of current standard of care in controlling plasma arginine levels"
08/05/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177"
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/24/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency"
05/07/2019 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design"
03/07/2019 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019"
11/08/2018 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights"
08/09/2018 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results"
05/08/2018 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results"
03/13/2018 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results Repeat Doses of Company’s Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels"
11/07/2017 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results"
08/09/2017 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results"
05/09/2017 8-K Form 8-K - Current report
03/23/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results"
05/19/2016 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy